Based on staging of preclinical AD with CSF biomarkers, Jack et al. recently recommended definitions of stage 1 and stage 2 as lowered CSF beta Aß42 and lowered Aß42 with rising Tau, respectively [4], [5]. Here, MAPT is linked to Alzheimer disease.